Prediabetes, Diabetes Mellitus, Osteoporosis
Conditions
Interventions
Observation group(Subproject 3):None
Observation group(Subproject 5):None
Observation group(Subproject 4):None
Sponsors
The Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age at onset >=18 years and =28 kg/m² (Subproject 3); 4. Signed informed consent (Subproject 3); 1. Identified as the reduced bone mass group or osteoporosis group based on dual-energy X-ray absorptiometry results (Subproject 4); 2. Voluntary participation and signed informed consent (Subproject 4); 3. Identified as the normal bone mass group based on dual-energy X-ray absorptiometry results (Subproject 4); 4. Voluntary participation and signed informed consent (Subproject 4); 1. Aged 18 years and older (Subproject 5); 2. Definitively diagnosed with an orthopedic disease, with clear surgical indications, and scheduled to undergo joint surgery or spinal surgery (Subproject 5); 3. Availability of complete preoperative imaging data, including one or more of CT, MRI, DR, or DXA (Subproject 5); 4. General condition adequate to tolerate surgery and anesthesia (Subproject 5); 5. Able to understand the study content and voluntarily participate in this research (Subproject 5); 6. Informed consent form signed by the subject or their legal representative (Subproject 5);
Exclusion criteria
Exclusion criteria: 1. other types of diabetes mellitus, including type 1 diabetes, specific types of diabetes, gestational diabetes mellitus, or unclassified diabetes(Subproject 3); 2. concurrent severe infection(Subproject 3); 3. severe dyspnea with oxygen saturation <92%(Subproject 3); 4. disturbance of consciousness or prior cerebrovascular disease(Subproject 3); 5. known severe cardiac, hepatic, or renal dysfunction(Subproject 3); 6. claustrophobia or other psychiatric disorders(Subproject 3); 7. pregnancy or lactation(Subproject 3); 8. malignant tumor or life expectancy <1 year(Subproject 3); 9. poor compliance as judged by the investigator, precluding completion of the study as required(Subproject 3); 10. concurrent participation in another randomized controlled study(Subproject 3); 1.Secondary osteoporosis (e.g. hyperparathyroidism, multiple myeloma, long-term use of glucocorticoids, etc.) (Subproject 4); 2. Other diseases affecting bone metabolism (Subproject 4); 3. Concurrent severe infection (Subproject 4); 4. Severe dyspnea with oxygen saturation < 92% (Subproject 4); 5. Consciousness disturbance or previous cerebrovascular disease (Subproject 4); 6. Known severe cardiac, hepatic, or renal dysfunction (Subproject 4); 7. Claustrophobia or other psychiatric disorders (Subproject 4); 8. Pregnant or lactating women (Subproject 4); 9. Malignant tumors or expected survival < 1 year (Subproject 4); 10. Patients judged by the investigator to have poor compliance and inability to complete the study as required (Subproject 4); 11.Concurrent participation in other randomized controlled trials (Subproject 4); 1.Concurrent severe infection (Subproject 5); 2. Severe dyspnea with oxygen saturation < 92% (Subproject 5); 3. Consciousness disturbance or previous cerebrovascular disease (Subproject 5); 4. Known severe cardiac, hepatic, or renal dysfunction (Subproject 5); 5. Claustrophobia or other psychiatric disorders (Subproject 5); 6. Pregnant or lactating women (Subproject 5); 7. Malignant tumors or expected survival < 1 year (Subproject 5); 8. Patients judged by the investigator to have poor compliance and inability to complete the study as required (Subproject 5); 9. Concurrent participation in other randomized controlled trials (Subproject 5);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolic indicators:blood pressure (BP), body mass index (BMI), waist circumference (WC), hip circumference (HC), and visceral fat area (VFA);Complication screening examinations: fundus photography, bilateral lower limb nerve conduction velocity (NCV) test, and color Doppler ultrasound of bilateral lower limb arteries.;Pancreatic islet function indicators: fasting C-peptide (FCP), fasting insulin (FINS), and oral glucose tolerance test (OGTT).;Lab indicators: HbA1c; liver function (ALT, AST); renal function (SCr);serum Uric Acid(UA);lipids (TC, TG, HDL, LDL); UAlb;UCr.; | — |
Countries
China
Contacts
Public ContactQiao Hong
The Second Affiliated Hospital of Harbin Medical University
Outcome results
None listed